Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1127-1129

  Butterfield, Joseph H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hematologic diseases; Human FIP1L1 PDGFR fusion protein; Hypereosinophilic syndrome; Imatinib mesylate; Interferon ; Mutation

Indexed keywords

FIP1L1 PDGFR ALPHA FUSION PROTEIN; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SULFALAZINE; TRYPTASE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ANOREXIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHILL; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOPENIA; DERMATITIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EOSINOPHILIA; FATIGUE; FEVER; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HAND EDEMA; HAY FEVER; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LABORATORY TEST; LEG EDEMA; LOW DRUG DOSE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOID HYPERPLASIA; LYMPHOMA; MALE; MOUTH ULCER; NIGHT SWEAT; ONCOGENE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT COURSE THERAPY; SKIN BIOPSY; SPHINCTEROTOMY; STENT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URTICARIA; XEROSTOMIA;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYUREA; HYPEREOSINOPHILIC SYNDROME; INTERFERON ALFA-2B; MALE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PREDNISOLONE; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TIME FACTORS;

EID: 67349095337     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.001     Document Type: Article

References (7)

1. Baccarani M., Cilloni D., Rondoni M., Ottaviani E., Messa F., Merante S., et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica 92 September (9) (2007) 1173-1179 Epub August 1, 2007
2. Pardanani A., Brockman S.R., Paternoster S.F., Flynn H.C., Ketterling R.P., Lasho T.L., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104 November (10) (2004) 3038-3045 Epub July 29, 2004
3. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 March (13) (2003) 1201-1214
4. Helbig G., Stella-Holowiecka B., Grosicki S., Bober G., Krawczyk M., Wojnar J., et al. The results of imatinib therapy for patients with primary eosinophilic disorders [letter to the editor]. Eur J Haematol 76 June (6) (2006) 535-536 Epub April 11, 2006
5. Muller A.M., Martens U.M., Hofmann S.C., Bruckner-Tuderman L., Mertelsmann R., and Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 85 January (1) (2006) 1-16 Epub September 1, 2005
6. La Starza R., Specchia G., Cuneo A., Beacci D., Nozzoli C., Luciano L., et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 90 May (5) (2005) 596-601
7. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 February (9) (2002) 645-652 Erratum in: N Engl J Med 2002 June 13;346(24):1923